Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy.

Multidrug-resistant (MDR) bacterial infections in humans are increasing worldwide. The global spread of antimicrobial resistance poses a considerable threat to human health. Phage therapy is a promising approach to combat MDR bacteria. An increasing number of reports have been published on phage therapy and the successful application of antibacterials derived using this method. Additionally, the CRISPR-Cas system has been used to develop antimicrobials with bactericidal effects in vivo. The CRISPR-Cas system can be delivered into target bacteria in various ways, with phage-based vectors being reported as an effective method. In this review, we briefly summarise the results of randomised control trials on bacteriophage therapy. Moreover, we integrated mechanisms of the CRISPR-Cas system antimicrobials in a schematic diagram and consolidated the research on phage-delivered CRISPR-Cas system antimicrobials. Copyright © 2021 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.

Citation

Ting-Kuang Yeh, Shio-Shin Jean, Yu-Lin Lee, Min-Chi Lu, Wen-Chien Ko, Hsueh-Ju Lin, Po-Yu Liu, Po-Ren Hsueh. Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy. International journal of antimicrobial agents. 2022 Jan;59(1):106475

Mesh Tags

Substances

PMID: 34767917

search → result